DMAC
DIAMEDICA THERAPEUTICS INC.Marquee-fund ownership over time
This quarter's activity
New positions opened
Positions exited
None.
Current holders
Sorted by tenure (longest first)| Fund | First disclosed | Held | Entry price | Latest close | Return on entry |
|---|---|---|---|---|---|
| Citadel Advisors re-entered | Q3 2024(8Q snapshot) | 7Q | $3.48 | $5.68 | +63% |
| Millennium Management re-entered | Q4 2024(8Q snapshot) | 6Q | $4.12 | $5.68 | +38% |
| AQR Capital Management | Q4 2025(8Q snapshot) | 2Q | $5.93 | $5.68 | -4% |
| Renaissance Technologies | Q2 2026(8Q snapshot) | 1Q | $6.36 | $5.68 | -11% |
“Return on entry” is the price-only move from the fund's first disclosure to today — it ignores any adds, trims, or dividends. A fund that built its position over multiple quarters has a true cost basis somewhere between entry price and latest close; this figure is the upper bound.
Insider activity
Form 4 — officers, directors, 10%+ ownersFiled within two business days of each transaction by anyone with material insider status at DiaMedica Therapeutics Inc.. Pair with the holders table above as a sanity check: heavy insider buying alongside marquee-fund accumulation is the strongest accumulation signal; heavy insider selling alongside fund exits is the strongest distribution signal.
30d / 90d windows measured from Jun 3, 2026 — the most recent Form 4 on file — not from today.
- Form 40001759822-26-000004Jun 3, 2026
- Form 40001341125-26-000002Jun 3, 2026
- Form 40001376847-26-000002Jun 3, 2026
- Form 40001451038-26-000002Jun 3, 2026
- Form 40001872863-26-000004Jun 3, 2026
- Form 40001759855-26-000004Jun 3, 2026
- Form 40001760123-26-000002Jun 3, 2026
- Form 40001490476-26-000002Jun 3, 2026
- Form 40001643127-26-000002Jun 3, 2026
- Form 40001759855-26-000002Jan 6, 2026
- Form 40001759822-26-000002Jan 6, 2026
- Form 40001872863-26-000002Jan 6, 2026
- Form 40001104659-25-119360Dec 8, 2025
- Form 40001759855-25-000006Nov 25, 2025
- Form 40001643127-25-000006Nov 3, 2025
Fundamentals
XBRL · DIAMEDICA THERAPEUTICS INC.Annual figures sourced directly from DIAMEDICA THERAPEUTICS INC.'s 10-K / 10-Q filings via SEC EDGAR XBRL. Latest fiscal year and the year-over-year change, with up to ten years of history.
Recent SEC filings
10-K · 10-Q · 8-K · 13D/G · proxyThe most recent material filings for DiaMedica Therapeutics Inc. — earnings, material events, ownership disclosures, proxy statements. Form 4 insider activity is shown in the panel above.
- 8-KFORM 8-KMay 21, 2026
- 10-QFORM 10-QMay 6, 2026
- 8-KFORM 8-KMay 6, 2026
- DEF 14AFORM DEF 14AApr 1, 2026
- 8-KFORM 8-KMar 31, 2026
- 10-KFORM 10-KMar 30, 2026
- 8-KFORM 8-KJan 5, 2026
- 8-KFORM 8-KDec 18, 2025
- 10-QFORM 10-QNov 12, 2025
- 8-KFORM 8-KNov 12, 2025
- 8-KFORM 8-KAug 12, 2025
- S-3FORM S-3Aug 12, 2025
- 10-QFORM 10-QAug 12, 2025
- 8-KFORM 8-KAug 12, 2025
- 8-KFORM 8-KAug 6, 2025
Trade history
Every open→close lifecycle across tracked funds| Fund | Open date | Close date | Open price | Close price / current | Return |
|---|---|---|---|---|---|
| Renaissance Technologies | Q2 2026 | open | $6.36 | $5.68 | -11% |
| Citadel Advisors | Q4 2025 | open | $5.93 | $5.68 | -4% |
| AQR Capital Management | Q4 2025 | open | $5.93 | $5.68 | -4% |
| Millennium Management | Q4 2025 | open | $5.93 | $5.68 | -4% |
| Millennium Management | Q4 2024 | Q3 2025 | $4.12 | $6.01 | +46% |
| Citadel Advisors | Q3 2024 | Q3 2025 | $3.48 | $6.01 | +73% |
- Covers only the 27 marquee funds tracked here, not the full institutional universe. A “0 holders” reading does not mean unowned.
- Heavy funds (Renaissance Technologies, Citadel Advisors, Soros Fund Management, Two Sigma Investments, D.E. Shaw, AQR Capital Management, Millennium Management, Point72 Asset Management) use 8-quarter snapshots, so their pre-2024 history is missing.
- “Current” reflects each fund's most recent 13F — filings lag the actual trade by up to 45 days; positions shown may have changed since.
- Cost = price at the entry filing date. Re-entered positions show the most recent open lot.
- Options, ADRs, and unmapped CUSIPs are excluded from the follower-backtest pipeline that produces these snapshots, so certain holding types won't appear here.